REDWOOD CITY, Calif., May 16, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from 18 separate studies covering breast, colon and prostate cancers will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, reflecting the company’s ongoing commitment to the research, development and delivery of innovative diagnostic tests to help individualize cancer treatment decisions. The annual meeting is taking place June 1-5, 2012 in Chicago, Illinois.
Key study results to be presented at the meeting include:
- Additional data on the clinical value of the Oncotype DX DCIS Score
- Further validation of the Oncotype DX colon cancer test
- Company’s first prostate needle biopsy study
- First Oncotype DX breast cancer treatment decision impact study results from Canada and France
- Multiple studies reconfirming the clinical utility and cost effectiveness of the Oncotype DX breast cancer test
The majority of ASCO Annual Meeting abstracts are now publicly available on ASCO’s website: www.asco.org.
Presentation details are as follows (all times are in Central Time):
DCIS Breast Cancer
Tuesday, June 5, 2012
Oral Presentation: “Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study” (Abstract #1005)
- Presenter:Sunil S. Badve, Indian University School of Medicine
- Session Time and Location:11:15 AM 11:30 AM; E Hall D1
Colon Cancer
Friday, June 1, 2012
Poster Discussion: “Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C-07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox)” (Abstract #3512)
- Presenter: Michael O’Connell, MD, National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital Cancer Center
- Poster Discussion Session Time and Location:1 PM 5 PM; E450b; E Arie Crown Theater
- Poster Board: #4
Monday, June 4, 2012
Poster Session: “Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer"(Abstract #3626)
- Presenter:Thomas H. Cartwright, MD, Ocala Oncology
- Session Time and Location:8 AM 12 PM; S Hall A2
- Poster Board: #37G
Prostate Cancer
Monday, June 4, 2012
Poster Discussion: “Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer” (Abstract #4560)
- Presenter:Eric A. Klein, MD, Cleveland Clinic
- Poster Discussion Session Time and Location:8 AM 12 PM; E450a
- Poster Board: #14
Invasive Breast Cancer
Saturday, June 2, 2012
Poster Session: “Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): focus on HER2, ER, PR, Ki-67 results from the Phase III WSG-Plan B trial” (Abstract #552)
- Presenter: Oleg Gluz, MD, West German Study Group
- Session Time and Location: 8 AM 12 PM; S Hall A2
- Poster Board: #3C
Poster Session: “Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France” (Abstract #568)
- Presenter: Joseph Gligorov, MD, PhD, Tenon Hospital, Paris
- Session Time and Location : 8 AM 12 PM; S Hall A2
- Poster Board: #5C
Poster Session: “Evaluation of Oncotype DX testing and subsequent patterns of care in patients (pts) with early-stage breast cancer (ESBC)” (Abstract #569)
- Presenter: Meghan Fitzgerald, MPH, MBA, Cardinal Health Specialty Solutions
- Session Time and Location: 8 AM 12 PM; S Hall A2
- Poster Board: #5D
Poster Session: “Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS)” (Abstract #555)
- Presenter: Kimberly Ridolfi, MD, University of Wisconsin
- Session Time and Location: 8 AM 12 PM; S Hall A2
- Poster Board: #3F
Poster Session: “Impact of exogenous female hormone use (EHU) on breast cancer (BC) recurrence as assessed by the 21-gene assay (Oncotype DX)” (Abstract #563)
- Presenter: Wendy M. Ledesma, MD, University of Wisconsin
- Session Time and Location: 8 AM 12 PM; S Hall A2
- Poster Board: #4F
Poster Session: “Evaluation of variables that may impact chemotherapy (CT) administration after determination of Oncotype DX (ODX) Recurrence Score (RS)” (Abstract #571)
- Presenter: Kristina E. Bowen, MD, Georgia Cancer Specialists
- Session Time and Location: 8 AM 12 PM; S Hall A2
- Poster Board: #5F
Poster Session: “A Prospective clinical utility study of the impact of the 21-gene Recurrence Score assay (Oncotype DX) in Estrogen Receptor Positive (ER+) Node Negative (pN0) Breast Cancer in Academic Canadian Centers” (Abstract #549)
- Presenter: James A. Davidson, MD, British Columbia Cancer Agency
- Session Time and Location: 8 AM 12 PM; S Hall A2
- Poster Board: #2G
Sunday, June 3, 2012
Poster Discussion: “Cost-effectiveness of the 21-gene recurrence core assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer” (Abstract #1525)
- Presenter: Shelby D. Reed, PhD, Duke University
- Poster Session Time and Location: 8 AM 12 PM; S102
- Poster Board: #14
Monday, June 4, 2012
Poster Session: "Relationship between Oncotype DX testing and the use of chemotherapy in high-risk patients (pts)” (Abstract #6098)
- Presenter: Winston Wong, PharmD, CareFirst BlueCross BlueShield
- Session Time and Location: 1:15 PM 5:15 PM; S Hall A2
- Poster Board: #8G
Poster Session: “Rural vs urban differences among patients (pts) with hormone-receptor positive (HR+) breast cancer (BC) and a 21-gene assay recurrence score (RS)” (Abstract #6063)
- Presenter: Molly Andreason, BS, University of Wisconsin-Madison
- Session Time and Location: 1:15 PM 5:15 PM; S Hall A2
- Poster Board: #4D
Poster Discussion: “10-year update of E2197: Phase III doxorubucin/docetaxel (AT) vs doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN + and high risk LN - breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features” (Abstract #1021)
- Presenter: Joseph A. Sparano, MD, Albert Einstein Cancer Center-Montefiore Medical Center
- Poster Session Time and Location: 1:15 PM 5:15 PM; E450b
- Poster Board: #13
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is a global health company that provides actionable genomic information to personalize genomic health decisions. The company’s lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. As of March 31, 2012, more than 10,000 physicians in over 65 countries had ordered more than 275,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.
Forward Looking Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to generate similar results in further studies; the ability of any tests the company may develop to optimize cancer treatment; the applicability of clinical study results to actual outcomes; our ability to develop and launch a test for prostate cancer in 2013; the ability of the company to develop additional tests in the future; the scope, success or results of clinical trials and the timing of such activities; and the ability of the company’s tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the risks associated with competition; the applicability of clinical study results to actual outcomes; the risks associated with the commercialization of current and future products; the risks and potential delays associated with such studies; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended March 30, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.
